KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Enterprise Value (2018 - 2025)

Historic Enterprise Value for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$287.6 million.

  • Castle Biosciences' Enterprise Value fell 277.82% to -$287.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$287.6 million, marking a year-over-year decrease of 277.82%. This contributed to the annual value of -$293.1 million for FY2024, which is 2058.05% down from last year.
  • Castle Biosciences' Enterprise Value amounted to -$287.6 million in Q3 2025, which was down 277.82% from -$275.9 million recorded in Q2 2025.
  • Castle Biosciences' Enterprise Value's 5-year high stood at -$225.5 million during Q2 2023, with a 5-year trough of -$407.0 million in Q1 2021.
  • In the last 5 years, Castle Biosciences' Enterprise Value had a median value of -$275.2 million in 2025 and averaged -$285.1 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 31253.79% in 2021, then surged by 2676.24% in 2022.
  • Quarter analysis of 5 years shows Castle Biosciences' Enterprise Value stood at -$329.6 million in 2021, then rose by 21.54% to -$258.6 million in 2022, then grew by 6.0% to -$243.1 million in 2023, then decreased by 20.58% to -$293.1 million in 2024, then increased by 1.89% to -$287.6 million in 2025.
  • Its Enterprise Value stands at -$287.6 million for Q3 2025, versus -$275.9 million for Q2 2025 and -$275.2 million for Q1 2025.